Vimarsana
Biggest News Aggregation in the World

Situ Using News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Situ Using. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Situ Using Today - Breaking & Trending Today

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference - Vimarsana News

PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...

PreludeDx™ to Present Multiple Presentations at the 2023 - Vimarsana News

PreludeDx™ to Present Multiple Presentations at the 2023

PreludeDx today announced that data will be presented in two separate poster presentations at the 2023 San Antonio Breast Cancer Symposium (SABCS)....

PreludeDx™ to Present New DCISionRT® Comparative Data in - Vimarsana News

PreludeDx™ to Present New DCISionRT® Comparative Data in

Data to Address Limitations in the Applications of Clinicopathologic Factors ...

PreludeDx Presents Comparative Data Analyzing Racial/Ethnic Radiation Therapy Treatment Recommendation Changes using DCISionRT - Vimarsana News

PreludeDx Presents Comparative Data Analyzing Racial/Ethnic Radiation Therapy Treatment Recommendation Changes using DCISionRT

Results show Black women had significantly higher rates of radiation therapy recommendation compared to White women with similar biosignature scores 

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium - Vimarsana News

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...